Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL825973 | 0.84 | AOC3 (0.50) | TAAR1AOC3ADRA2AADRA2CCYP2D6 | |
| SCHEMBL3886956 | 0.77 | AOC3 (0.45) | TAAR1AOC3ADRA2AADRA2CCYP2D6 | |
| SCHEMBL17084095 | 0.75 | ADRA2C (0.48) | TAAR1AOC3ADRA2AADRA2CCYP2D6 | |
| SCHEMBL21789841 | 0.75 | ADRA2C (0.48) | TAAR1AOC3ADRA2AADRA2CCYP2D6 | |
| SCHEMBL8089536 | 0.75 | TSHR (0.48) | TAAR1AOC3ADRA2AADRA2CCYP2D6 | |
| SCHEMBL17084114 | 0.75 | ADRA2C (0.48) | TAAR1AOC3ADRA2AADRA2CCYP2D6 | |
| SCHEMBL9239618 | 0.75 | TSHR (0.48) | TAAR1AOC3ADRA2AADRA2CCYP2D6 | |
| SCHEMBL16233141 | 0.75 | ADRA2A (0.54) | TAAR1AOC3ADRA2AADRA2CCYP2D6 | |
| SCHEMBL8094329 | 0.75 | AOC3 (0.43) | TAAR1AOC3ADRA2AADRA2CCYP2D6 | |
| SCHEMBL15222220 | 0.75 | ADRA2C (0.48) | TAAR1AOC3ADRA2AADRA2CCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344019-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3397706-A1 | ANTI-BIOFOULING COATING BASED ON EPOXY RESIN AND AMINE-FUNCTIONAL POLYSILOXANE | Dow Global Technologies LLC (US) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017113149-A1 | ANTI-BIOFOULING COATING BASED ON EPOXY RESIN AND AMINE-FUNCTIONAL POLYSILOXANE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-07-06 | — | — | WO | disclosed |
| EP-0669949-B1 | TERTIARY AMINE DERIVATIVES AS COMPONENTS OF POLYMER FORMING SYSTEMS | COGNIS CORP (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-0669949-A4 | TERTIARY AMINE DERIVATIVES AS COMPONENTS OF POLYMER FORMING SYSTEMS. | HENKEL CORP (US) | 1996-07-10 | — | — | EP | disclosed |
| EP-0669949-A1 | TERTIARY AMINE DERIVATIVES AS COMPONENTS OF POLYMER FORMING SYSTEMS | HENKEL CORPORATION (US) | 1995-09-06 | — | — | EP | disclosed |
| US-5444127-A | Urea, thiourea, guanidine derivatives, curing agents for epoxy resins, odorless, low temperature | HENKEL CORPORATION (US) | 1995-08-22 | — | — | US | disclosed |
| WO-1994009051-A1 | TERTIARY AMINE DERIVATIVES AS COMPONENTS OF POLYMER FORMING SYSTEMS | HENKEL CORPORATION (US) | 1994-04-28 | — | — | WO | disclosed |
| EP-0014745-B1 | CURING AGENT FOR POLYEPOXIDES, CURABLE EPOXY RESIN COMPOSITIONS, HARDENED PRODUCTS THEREFROM AND PROCESS FOR CURING A POLYEPOXIDE | DIAMOND SHAMROCK CORPORATION (US) | 1983-05-25 | — | — | EP | disclosed |
| EP-0075827-A2 | Polyepoxide curing by polymercaptans plus catalytic co-curing agents | DIAMOND SHAMROCK CHEMICALS COMPANY (US) | 1983-04-06 | — | — | EP | disclosed |
| EP-0014745-A1 | Curing agent for polyepoxides, curable epoxy resin compositions, hardened products therefrom and process for curing a polyepoxide | DIAMOND SHAMROCK CORPORATION (US) | 1980-09-03 | — | — | EP | disclosed |
| US-4177173-A | INFUSIBLE FILMS, CASTINGS OR ADHESIVES | DIAMOND SHAMROCK CORPORATION (US) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344019-B2 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | TAAR1 4811/4885AOC3 4153/4885ADRA2A 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.